nih glp 1 A team of researchers from the National Institutes of Health (NIH), Copenhagen University Hospital, and international collaborators has reported the first evidence from a randomised controlled clinical trial showing that a GLP-1 Glucagon-like peptide-1 receptor: mechanisms and

Outcomes 16 , e009078 (2023)

Gut microbiome analysis could guide probiotic and prebiotic interventions that optimize both natural GLP-1 production and autoimmune management

Quitting is notoriously difficult because nicotine addiction is multifactorial

Last year, the American Academy of Pediatrics issued recommendations that obesity drugs may be considered for kids 12 and older with obesity

As scientists in the drug delivery field we often focus on engineering products for maximizing plasma half-life and investigating mechanisms to achieve it

Resistance training preserves muscle mass One of the legitimate concerns about GLP-1 medications is muscle loss during weight reduction